Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid...
March 17, 2026 07:50 ET | Source: Neuronetics

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

Total revenue of $41.8 million in Q4 2025, up 86% as reported and 23% on an adjusted pro forma basis versus Q4 2024 Greenbrook clinic revenue of $23.5 million in Q4 2025, up 428% as reported and 37%...
March 17, 2026 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...
March 17, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,...
March 17, 2026 07:30 ET | Source: Knight Therapeutics

Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico

MONTREAL, March 17, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Argentine affiliate,...
March 17, 2026 07:00 ET | Source: Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis
March 17, 2026 07:00 ET | Source: Telesat

Telesat reports results for the quarter and twelve months ended December 31, 2025

OTTAWA, Ontario, March 17, 2026 (GLOBE NEWSWIRE) -- Telesat (Nasdaq and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the...
March 17, 2026 07:00 ET | Source: Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
March 17, 2026 07:00 ET | Source: H&R Block Canada Inc.

Two-Thirds of Canadians (67%) Say it’s Time to Abolish Tips, Reveals New H&R Block Canada Study

CALGARY, Alberta, March 17, 2026 (GLOBE NEWSWIRE) -- While nearly one in three (31%) Canadians have worked in a gratuity-based job at some point*, a new 2026 survey commissioned by H&R Block...
March 17, 2026 06:00 ET | Source: Greenwich LifeSciences, Inc.

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

STAFFORD, Texas, March 17, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...